- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 .
|Despite peptide matches suggesting that dusigitumab is antibody 7_159_1 (or 7.159.1) in patent US7939637 , no data is presented for this clone. Data is presented for 7.159.2, but crucially no sequence data is available. The binding data we present here is for antibody clone 7.159.2 as a representative example from the patent.|
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|